Oncogenic mutations in the small Ras GTPases KRas, HRas, and NRas render the proteins constitutively GTP bound and active, a state that promotes cancer [1] . Ras proteins share w85% amino acid identity [2] , are activated by [3] and signal through [4] the same proteins, and can exhibit functional redundancy [5, 6] . Nevertheless, manipulating expression or activation of each isoform yields different cellular responses [7] [8] [9] [10] and tumorigenic phenotypes [11] [12] [13] , even when different ras genes are expressed from the same locus [6] . We now report a novel regulatory mechanism hardwired into the very sequence of RAS genes that underlies how such similar proteins impact tumorigenesis differently. Specifically, despite their high sequence similarity, KRAS is poorly translated compared to HRAS due to enrichment in genomically underrepresented or rare codons. Converting rare to common codons increases KRas expression and tumorigenicity to mirror that of HRas. Furthermore, in a genome-wide survey, similar gene pairs with opposing codon bias were identified that not only manifest dichotomous protein expression but also are enriched in key signaling protein classes and pathways. Thus, synonymous nucleotide differences affecting codon usage account for differences between HRas and KRas expression and function and may represent a broader regulation strategy in cell signaling.
limits protein expression. KRAS* still expressed less protein than HRAS (Figures 1A, S1A-S1C, and S1E-S1G); whether this is a consequence of the remaining KRAS sequence or is due to other mechanisms remains to be determined. Additionally, pERK and pAKT levels, measures of Ras effector activation, were similar in cells expressing oncogenic HRas, KRas, or KRas* ( Figure S1G ). Brief metabolic labeling revealed higher KRas protein expression from KRAS* compared to KRAS (Figure S1J ), consistent with a translational etiology. Indeed, glutathione S-transferase (GST) fused with KRAS cDNA (GST-KRas) expressed little protein unless a STOP codon was inserted between the two (GST-STOP-KRas) or KRas protein was encoded from KRAS*, suggesting that ribosomes stall upon entering KRAS mRNA ( Figure 1B ). Moreover, KRAS and KRAS* mRNA levels were within 2-fold of HRAS mRNA ( Figure S1K ), although KRAS was consistently the lowest, perhaps reflecting no-go decay of stalled transcripts [14] . Thus, the nucleotide sequence of KRAS message impedes translation.
Comparing the KRAS and HRAS sequence revealed that the third position of codons was typically an A/T in KRAS but G/C in HRAS. Based on human genome-wide analysis of the relative frequencies that degenerate codons are used to encode for the same amino acid [15] , the A/T bias in KRAS corresponds to underrepresented (rare) codons ( Figure 1C ). Consistent with rare codons limiting protein expression, KRas levels were increased when translated from KRAS* mRNA ( Figure 1A) . Similarly, the bias toward rare codons was conserved in mammalian and avian KRAS genes (Figure S1L ) and equated with lower expression compared to HRas in mammalian cells ( Figure 1D ). Moreover, zebrafish hras and kras encoded by a mixture of rare and common codons exhibited comparable protein expression at a level between that of mammalian HRas and KRas ( Figures 1D and  S1L ). Finally, progressively converting rare to common codons proportionally increased human KRas protein expression, even upon changing only nine rare isoleucine and valine codons scattered throughout KRAS to their common counterparts ( Figures 1E and S1I ). Thus, rare codons limit KRAS translation.
To investigate this phenomenon at the endogenous level, we infected HCT116 human cancer cells (which have a KRAS G13D allele) with an AAV targeting vector [16] designed to knock into KRAS exon 1 either opKRAS G13D (oncogenic KRAS G13D cDNA in which 130 rare codons were optimized to common codons) or uaKRAS G13D (unaltered KRAS G13D cDNA). The resultant transcripts would be expressed from the endogenous KRAS promoter and retain the 5 0 UTR and first 17 coding nucleotides, minimizing effects on translation initiation, but encode only the KRAS4B spliced product (Figure 2A ). Screening w1,800 neomycin-resistant clones revealed four with opKRAS
G13D
and two with uaKRAS G13D cDNA successfully knocked into one allele of the KRAS gene. Immunoblot revealed poor expression of endogenous KRas in both the uaKRAS G13D and control cell lines exhibiting a random integration event, on par with the parental HCT116 cells. Conversely, the opKRAS G13D cell lines exhibited on average 5-fold higher KRas protein and 2-fold higher KRAS mRNA levels ( Figures 2B, S2A , and S2B). This increase was lower compared to the ectopic setting, consistent with overexpression systems magnifying the effects of codon bias [17] . Thus, changing rare to common codons increases endogenous KRas protein expression.
Polysome profiling was performed to characterize relative ribosomal kinetics of endogenous HRAS and endogenous untargeted KRAS mRNAs from HCT116 clone 5. Semiquantitative RT-PCR revealed that both transcripts accumulated in polysome fractions, although KRAS occupied relatively heavier fractions despite nearly equal transcript length (Figure 2C) , indicating more dense packing of ribosomes. Pactamycin treatment to halt translation initiation ( Figure S2C ) led to an accumulation of HRAS mRNA in lighter polysome and ribosome-free fractions, indicative of ribosome translocation. As observed previously [18] , there was only a minimal shift of KRAS mRNA in the gradient, with the bulk of the message retained in the heavy fractions ( Figure 2C ). These results were confirmed in HEK-HT cells ( Figure S2D ). Polysome profiles of mRNA derived from the opKRAS G13D HCT116 clone 5 and uaKRAS G13D HCT116 clone 1 were compared. Quantitative RT-PCR analysis revealed that after pactamycin treatment ( Figure S2C ), opKRAS G13D mRNA was modestly shifted to lighter fractions relative to uaKRAS G13D mRNA ( Figure 2D ), consistent with the degree that other transcripts are shifted upon alleviating ribosome stalling [19] . These shifts were recapitulated in opKRAS G13D HCT116 clone 4 (Figures S2C and S2E). Thus, rare codons impede translation of endogenous KRAS mRNA.
The biological impact of codon bias in mammalian genes is largely unknown. However, targeted replacement of codons in the Drosophila alcohol dehydrogenase gene with either suboptimal [20] or optimal [21] codons can respectively decrease or increase enzyme activity and alcohol tolerance, suggesting that codon bias affects gene function in higher eukaryotes. Because oncogenic Ras can impart tumorigenic growth to cells, we used tumor growth to assess the biological impact of altering codon bias of human KRAS. HEK-HT cells, which require oncogenic HRas for tumor growth [22] , were transduced with a vector expressing no transgene, oncogenic HRas G12V , KRas G12V , or KRas* G12V ( Figure 1A ) and assayed for tumor growth. KRas G12V , like vector cells, formed tumors with 90-fold smaller masses and reduced kinetics compared to HRas G12V cells, an effect rescued by KRAS*
G12V
( Figures 3A-3C ). Tumors that eventually formed 3 months later from KRas G12V cells exhibited elevated KRas expression ( Figure S3A ). To examine the endogenous effect, we compared opKRAS G13D and uaKRAS G13D knockin clones in which targeted recombination occurred at the same wildtype KRAS allele. opKRAS G13D clone 5 formed tumors with up to 30-fold larger masses and increased kinetics compared to uaKRAS G13D clones ( Figures 3D-3F ), although this was not as dramatic as observed in the ectopic setting. Tumors from opKRAS G13D cells retained differential KRas protein expression and, interestingly, exhibited higher HRas expression (data not shown). Although altering rare codons may affect protein folding and processing [17] , there is a direct correlation among codon content, protein expression, and tumorigenesis of ectopic and endogenous oncogenic KRAS.
To explore whether the differences in codon bias between RAS genes reflect a broader regulation strategy, we performed a genome-wide survey to identify gene pairs with high similarity and divergent codon usage (Table S1 ) using G-C content at synonymous sites (GC3) as a proxy for rare codons [15] . Using KRAS and HRAS as a benchmark, the top 60 gene pairs had R80% amino acid identity and R1.8-fold difference in GC3 content ( Figure 4A ; Table S1 ). Twelve such cDNA pairs were Myc epitope tagged and expressed in human cells. In every case, the gene enriched in rare codons expressed less protein. Changing rare to common codons in the two genes CFL2 and ORMDL1 augmented protein expression to that of CFL1 and ORMDL3 ( Figure 4B ). Thus, synonymous differences altering codon usage influence expression of mammalian genes encoding similar proteins.
To assess the functional significance of this gene set, we performed gene ontology analysis [23] on the top 150 gene pairs sharing high identity and large differences in GC3 content (Table S1 ). Strikingly, we found that this set was highly enriched for proteins with purine nucleotide binding or kinase activity. This enrichment was six or more orders of magnitude more significant than enrichment of any other functional category from the analysis of gene pairs from complementary combinations of identity and GC3 content criteria ( Figure 4C ; Table S2 ). KEGG pathway analysis [24] was also performed to determine whether gene pairs reside in pathways. Insulin signaling, long-term potentiation, and tight junction pathways, in particular, were significantly enriched for gene pairs with high protein identity and differential codon usage ( Figure 4D ; Table S3 ). Thus, the combination of two seemingly unrelated criteria-high protein identity and opposing codon bias-identified unique functional classes of proteins as well as signaling pathways.
Discussion
Although differences in KRas and HRas expression have been previously reported in at least some settings [25] , the mechanism responsible and effects thereof remained unknown. Here we present a novel regulatory strategy that has been hiding in plain sight: codon bias. Rare codons throughout KRAS message impede translation and correspondingly protein, and to a lesser extent mRNA levels, and reduce oncogenic activity. This was surprising because, although rare codons impede protein translation in heterologous expression systems [26, 27] and common codon bias exists in highly expressed genes in bacteria and yeast [17] , there are few reports of it affecting ectopic expression of homologous transcripts [28] [29] [30] , let alone endogenous mammalian genes. Moreover, codon bias in mammals has been argued to be a by-product of genes residing within larger genomic regions of nucleotide bias (isochores) that affect chromatin functions like meiotic recombination [31] . Furthermore, in genome-wide translational assessment, sites of ribosome stalling do not correlate with presence of rare codons [32] . Nevertheless, the effects of codon usage between RAS genes on protein expression and function suggest that there are indeed consequences resulting from synonymous differences at the nucleotide level [20, 21, 33] .
At face value, the finding that KRAS is an incredibly weak oncogene due to rare codon bias seems at odds with this gene being the most commonly mutated RAS isoform in cancer [34] . However, untransformed cells are sensitive to oncogenic stress [35] , and increasing levels of transgenic Hras G12V result in progressively more growth-arrested (senescent) cells and fewer mammary lesions in mice [36] . Perhaps rare codons limit the expression of KRas to an ideal range to initiate tumorigenesis-high enough to promote hyperplasia but low enough to avoid excessive senescence. Indeed, IMR90 primary human fibroblasts expressing KRAS* G12V or HRAS G12V , but not KRAS G12V , appeared to arrest with a senescent morphology ( Figure 3G ; data not shown). Interestingly, there is concordance between the degree of rare codon bias and the mutation frequency among RAS family members (Figures S3B and S3C) . However, codon bias cannot alone account for this difference, because Hras cDNA knocked into the Kras locus is mutated at a high frequency in a urethane model of lung cancer [6] . Nevertheless, rare codons clearly crippled the oncogenic activity of KRAS, which could be a barrier to malignant progression. In this regard, it has been hypothesized that upregulation of oncogenic KRas is a necessary intermediate step in tumor progression after senescence escape [36] . Multiple mechanisms that may increase KRas expression occur during cancer, including KRAS gene amplification [37, 38] , microRNA downregulation directly [39, 40] or indirectly by sequestration via KRAS pseudogene mRNA [41] , and a general increase in tRNA levels [42, 43] .
It was also striking that the divergent tumorigenesis phenotypes of two nearly identical proteins were reconciled by altering codon usage. It is formally possible that changing codon bias affected some other aspect of mRNA regulation, but the multitude of complementary codon modification strategies implemented make this possibility less likely. Codon usage might underlie functional differences between members in other protein families with opposing codon bias. The enrichment of gene pairs with high amino acid sequence identity and divergent codon bias in signaling networks further suggests that codon usage may impact entire signaling pathways. Indeed, differential regulation of functionally redundant genes may add specificity to signal transduction [44] , and there are situations in which transcripts enriched in rare codons are preferentially translated in mammalian cells [45] . Thus, codon bias is not only a novel mechanism regulating Ras isoforms but may reflect a broader regulatory strategy in signaling pathways. Tables S1, S2 , and S3.
